OPEN ACCESS Freely available online

Journal of Pharmacovigilance

Review Article

Adverse Drug Reactions and Pharmacovigilane of Herbal Drugs

Subhash Kumar Ojha[1*], Sharad Wakode[2], Avneet Kaur[3], Nikita Verma[4]

[1,4]Department of Pharmaceutical chemistry, M. Pharm Research Scholar, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi 110017, India, [2,3]Department of Pharmaceutical chemistry, Faculty of Pharmacy, Delhi, [4]Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi 110017, India

ABSTRACT

Introduction: There are significant problems in using conventional pharmacovigilance methodologies to investigating the efficacy and safety of herbal medications, especially when utilized by indigenous populations. Various levels of government are becoming more conscious of need to create pharmacovigilance standards for herbal medications.

Methods: The existing pharmacovigilance paradigm and techniques were created in connection to synthetic pharmaceuticals, and using those techniques to assessing the efficacy of herbal supplements offers new problems in contrast to all those outlined for standard treatments.

Result: The goal of pharmacovigilance would be to identify, analyse, and comprehend detrimental consequences and other potential medication problems associated with natural, traditionally, and supplementary treatments, as well as to avoid them.

Keywords: herbal; plants; remedies; adverse reactions; pharmacovigilance

INTRODUCTION

Pharmacovigilance seems to be the research and activities concerned with the identification, evaluation, comprehension, and mitigation of adverse medication effects and perhaps other potential medication issues. Herbs, alternative and traditional treatments, blood products, and biological has lately been added to the list of issues. The goal of pharmacovigilance should be to identify, analyse, and explain negative impacts as well as other potential medication issues.This includes not just chemical pharmaceuticals, and moreover herbs, customary, and medicinal products, biological, vaccine, tissue samples, and medical equipment. Herbal plants have been used as medicine for as long as civilization has existed. According to some researchers, the earliest known usage of plants for medicinal therapy occurred around four thousand years ago [1].The form of medical therapy originated in India and China. Chinese Medicine focuses mostly on connections between system and its environment. Then, a combination of therapies, involving botanicals, acupressure, and physiotherapy, is recommended. Indian Traditional medicine dates back to 3000 BC years [2-9]. Ayurvedic medicine became one type of traditional Indian system of medicine [10-13]. Herbal treatment began relatively recently in the United States, coinciding with the nation's formation. A blend of Chinese, European, Ayurvedic, and other alternative therapies has impacted the usage of plants here to current day. Adverse reactions also may occur as a result of using the incorrect species of traditional medicines, inaccurate dosages, and inaccuracies with the use of herbal drugs by medical care suppliers and customers, encounters with some other medications, including the use of contaminated products with possibly toxic chemicals like heavy metals, microbial pathogens, and pesticide particulates [14-20].

The WHO Collaborating Centre for International Drug Monitoring has suggested use of real scientific binomial identities for medicinal plants used during medications, through the use of those names (in which this data is accessible) throughout the scripting of adverse reaction (AR) findings, in attempt supply uniformity throughout the labelling of medicinal plants in adverse reaction (AR) report [21-26].It could guarantee that data from multiple worldwide pharmacovigilance platforms are

***Correspondence to:** Subhash Kumar Ojha, Department of Pharmaceutical chemistry, M. Pharm Research Scholar, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi 110017, India, Tel: 8527505908; E-mail: Skumarojha92@gmail.com

Received date: July 30, 2021; **Accepted date:** October 12, 2021; **Published date**: October 26, 2021

Citation: Ojha SK, Wakode S, Kaur A, Verma N (2021) Adverse Drug Reactions and Pharmacovigilance of Herbal Drugs. J Pharamacovigil 9:p309.

comparable. Publishers of printed AR published studies must also specify the exact products / services) implicated, particularly labelling and supplier details, specific components, and dosage used [27].

PHARMACOVIGILANCE CHALLENGES OF HERBAL PRODUCTS

Herbal Medication Users as a Source

Customers appear to self-prescribe natural medications before contacting a qualified medical therapist or even other healthcare provider, according to studies. With no consulting a medical expert, items can be bought over-the-counter from drugstore, stores, marketplaces, or even online. In such European nations (for example, Germany), natural medications are prescribed by traditional healthcare professionals. Patients could be unaware that bad effects with medicinal herbs can be notified to the healthcare professional and that regulatory bodies could be contacted. Furthermore, customers may well not link the natural medicine with result. Several researchers have discovered that customers were hesitant to confess to the doctor that they've been taking natural medications. Several customers may seek the advice of medicinal professionals, however at the moment, rules governing who would offer natural medications vary greatly throughout Europe[28]. With highly qualified experts to unskilled and uncontrolled persons, knowledge and practice standards differ [29].

Properties of Herbal Plants

Herbal medications, in relation to standard medications, are chemically diverse complex combinations containing hundreds of ingredients. The molecular medicinal components of several natural supplements are unclear, and among those having bioactivities, there's few whose particular components essential for therapeutic effects are well recognized[30].

The component structure of a species is rarely homogeneous, so for many species, just a single plant portion or sections, like leaves and roots are utilized for medicinal purposes. Furthermore, the exact component composition is capable of altering either quantitatively and qualitatively across sets of plant raw material due to following factors:

- Environmental variables like as temperature and growth circumstances
- Intra- or interspecies variance in components.
- Harvesting period — the component profile might change even within a single day
- Post-harvesting variables like drying and processing conditions.

Due to the extreme differences that could occur here between items of various producers and formulations of same plant component, proof of efficacy is required must be viewed throughout this perspective; technically accurate, data- or extract-specific, and can only be extended to certain medicines or preparations that have already been demonstrated to be pharmacologically similar and bioequivalent.

Ayurvedic Medication Utilization and Associated Problems

Herbal remedies are utilized by a diverse variety of people in the United Kingdom both for acute and chronic illnesses. Numerous herbal medical items are bought to maintain overall health and well-being, and to diagnose and reduce small, serious ailments. People with significant chronic illnesses, such as leukaemia, AIDS, sclerosis, and asthma, and many other ailments, utilize plant medical products, and so do geriatric patients and breastfeeding and pregnant females, and parents provide natural herbal products to their kids. In a short research done in the United Kingdom, 59 percent of traditional medicinal consumers detected in drugstore and super markets reported using natural remedies simultaneously with traditional treatments, primarily prescription medications, in the preceding year. A significant issue is that a few medicinal herbs consumers may well not reveal ones use to a medi care professional; similarly, health professionals may not regularly ask to their clients if they are using natural remedies, even though retrieving data from consumers with suspected ADRs compared with standard medications, and rarely reveal data on medicinal herbs use with the health records. Research published in other industrialized nations, like Australia and the United States; indicate an increase with the use of medicinal herbs among adult population. Generalizing estimations of herbal remedies usage from certain research indicates that huge percentage of people are now being treated to herbal medications, which is concerning for human health [31-36].

Herbal Medicine Regulatory Framework

The need for such a regulatory regime for natural medical goods was initially raised in the 1980s, and it is already widely acknowledged that now the present regulatory system does not sufficiently safeguard population health for a range of factors. 18 The current structure, in instance, has not enough security to customers and consumers from low-quality, dangerous unregistered herbal medical goods. It also segregates towards producers of registered herbal medical goods, whose prices are considerably higher due to the requirement to adhere to good manufacturing practice standards as well as other legal regulations. In context of all this, a draft European Union herbal medicinal formulation which provide comprehensive in- (EU) directive (2002/0008, that reforms 2001/83/ EC) was already developed with the goal of establishing a standardised regulatory framework for approving the advertising of standard herbal medicines interviewing specific measures. 19 Once implemented, the draft regulation will also have a significant influence on herbal medication pharmacovigilance. Producers of herbal medicinal goods licensed under directive's UK national system would be obliged to comply with applicable current pharmaceutical law, particularly pharmacovigilance regulations. Many of that may provide challenges for producers with no expertise in this field. For instance, the obligation to have continual access to either a pharmacovigilance professional who is suitably highly trained the adoption of the usage of the Medical Dictionary for Regulatory Activities (MedDRA), and access to it and conformity to Eudra-Vigilance. As per the

present schedule, the regulation is anticipated to enter to effect in 2020, with a transitional minimum period five years (the time period is now in discussion but it could be seven years).

PHARMACOVIGILANCE METHODS

For post-marketing medication safety surveillance, a variety of approaches are employed, namely spontaneous reporting and prescription event tracking. Such approaches will be used to assess herb efficacy, but they must be modified to meet particular issues like plant taxonomy, purity, adulteration, labelling concerns, reporter discrepancies, or under [37].

Spontaneous Reporting

Medication efficacy is often checked via spontaneous reporting mechanisms. There have been minor changes across nations; however the fundamentals are still the same. Highly standardized form is being used by healthcare experts, including doctors, chemists, nurse, or, in certain nations, customers, to report potential adverse effects to regulatory bodies. The findings are of 'suspected' negative effects, and a researcher is not needed to verify the link among medication and impact. The monitoring centers evaluate this causation on a specific instance basis. Analytical techniques are used to analyse abnormal rates that might indicate a safety issue. A' signal' simply suggests an undesirable impact of concern that has to be evaluated and investigated more - the relationship to a medicine or plant is not verified. Spontaneous reports are much more likely to be successful when goods are controlled as medications and thus are provided by medical practitioners who are well-versed in the usage of such a tracking system. People could be unaware of a significance of identifying unfavorable consequences [38].

Within United Kingdom, the Medicines and Healthcare Products Regulatory Agency receives around 20,000 yellow card submissions every year, but only approximately 100 of them are plant-based investigations. With initiatives to boost monitoring by include doctors, chemists, and customers; there is no discernible rise in herbal reporting. Medicinal adverse drug reactions have been studied in nations like as Italy and Sweden. As there are very few 'yellow card' herbs complaints throughout the UK, identifying negative impacts of interest by evaluating individual investigations with no waiting for statistics signal analysis is quite simple.

Producers has pharmacovigilance duties within European directives and possibly extra National legislation when medications are controlled (e.g., recognized too though recognized or herbal medicinal product in Europe). Those standards apply to both conventional and natural medications. It involves deadlines as well as other reporting obligations for alerting regulatory bodies of every instance of undesired or unanticipated adverse effects from the goods. The order does not apply to unregistered or unlicensed goods or nutritional supplements.

Prescription Event Monitoring (PEM)

This is a non-interventional idea generation technique for investigating a medication after it has been commercialized, using personal prescription tracking. Depending on tracking prescription from plant therapists, a modified strategy for utilizing PEM for medicinal herb has indeed been established in the United Kingdom. This is a good way to look at particular safety issues about commonly utilized medicinal plants.

Intensive monitoring programs are used to encourage monitoring on certain drugs but are an expansion of spontaneous reporting initiatives. There seems to be a long list of recognized medicinal herbs in Thailand which are also utilized in clinics. It employed extensive monitoring for 9 distinct herbal items when more safety data was required. The Poisons Control Centres are also another resource of pharmacovigilance and safety data on herbal medications. Such centres accept inquiries in Europe and the United States if there are concerns about the impact of a commodity or a potential poisoning [39-41].

Because these inquiries are not always official complaints, additional data on sales specifications, time course, and dose could be absent. Individuals might well have consumed a chronic or acute excess and are requesting medical treatment; however, it may not provide relevant information about long-term toxicity. Poisons Control Centres are a major source of dietary additive adverse drug reactions throughout the United States, according to a 2008 research that found that perhaps the principal reporting site, MedWatch, got less complaints than that of the poison centers. Case studies are another type of pharmaco- epidemiological approach which can be used to investigate the efficacy of medicinal herbs. Those are used to evaluate assumptions generated following the detection of signals via spontaneous reporting. This one signal has been found in claims of potential liver damage related through the use of Chinese medicines. A pilot case - control report has been utilized to show there was no significant connection between liver damage as well as any particular ingredient.

Issues with Spontaneous Reporting

In spontaneous management system, less reporting has been a known issue. It is believed to become a more serious issue with herbal medications. The following factors contribute to the less-reporting of plant adverse reactions:

- There is no link here between plant and the negative impact.
- When the individual becomes ill, they discontinue use of the herbal medication.
- The doctor or consumer is uninformed that plant adverse reactions must be mentioned.
- The doctor is ignorant of use of herbal medications because the consumer may not understand natural based products to be "remedies" and thus do not reveal their usage.

Herbal items contaminated with prescription medications for reducing (sibutramine), corticosteroids, or sildenafil as a sexual dysfunction treatment are a worldwide issue. During an examination of plant safety alerts published in year 2010, they

discovered that drug contaminants or spoilage contributed for 336 of 390 cautions established by government agencies in the United States, Australia, United Kingdom, Singapore, Canada, and Hong Kong.

With just a small number of adverse reactions complaints in a nation state, natural indications of relevance may be missed, particularly for uncommon responses. The WHO Collaborating Centre for Monitoring Drug Safety (UMC) is attempting to solve this issue by compiling adverse drug reactions data over 100 countries. The dataset includes approximately 6 million medication and plant complaints by 2011. It is the most comprehensive archive of these data. They sought to resolve nomenclature difficulties as plant evidence came across nations with various traditional systems of medicine. But, the content of various herbal remedies varies; attention is advised when mixing data on a single plant. Groups of plants having chemically similar compositions, but at the other hand, could be analysed to recognize signals for more research.

HERBAL DRUG BASED ADVERSE REACTIONS

The use of herbal medications grew in the previous few decades, so did complaints of toxic effect and adverse effects. A meta-analysis of 69 retrospective and prospective investigations from diverse parts of the world including 419 000 participants revealed that adverse events accounted for roughly 6.7 percent of all hospitalizations. And over 50% of adverse events which happened might be avoided if treatment methods had been modified (monitoring reactions, prescriptions, etc.). 27.6 percent of adverse outcomes were deemed avoidable, and 38 percent were classified as severe, life-threatening, or deadly.

As just an instance of harmonization, UMC accepts ADR complaints of over 100 countries worldwide, and its database included over 4 million complaints in year 2010 (about 21,000 of them were natural or herbal goods. Adverse events have clearly has become serious global health problem. Adverse responses can occur as a result of:

- Adverse effects (generally observable by pharmacodynamics and frequently predicted); for example, feverfew has known adverse effects like inflamed tongue and mouth ulcers.
- Tolerance, overdosage, excessive time, dependence-addiction responses, e.g., high doses of Ginkobiloba could even provoke a few other mild symptoms like stomach ache, nausea, drowsiness, indigestion, and vigorous pulse, combined effect to anticoagulants have shown no similarity to the threat of haemorrhage.
- Sensitization, allergy, and idiosyncratic responses are all possible. For example, hypersensitive responses to chamomile as well as other herbs in a same Compositae family (Asteraceae) have been observed.
- Early and lengthy harmful effects include hepatic, kidneys, cardiovascular, and neurotoxicity, as well as teratogenic effects and genotoxicity (traceable through in vivo or in vitro toxicity studies or surveillance).

Because safety is also not taken into account in alone, the effectiveness of herbal medications is significant too. Despite the common usage of herbal remedies across the globe, there's little scientific proof of efficiency for the majority of them: the safety of several medicinal herbs has still not been tested in controlled clinical studies. Particularly with some tested herbal medicines, like various St John's wort preparations, which were evaluated from over 30 randomised clinical studies in depression, limited test subjects have been subjected to a single company's medication. Moreover, there have been few long-term clinical studies of herbal medicines for long-term usage. Traditional medications, from the other hand, would have been evaluated in up to 5000 people until it comes to market, and all this is regarded a tiny amount. The lack of knowledge about the efficacy and safety of plant medical items makes determining the benefit-to-harm ratio challenging. Medicinal herbs medications are thought to be harmless since these are derived by “natural” origins Furthermore, many plants are extremely dangerous, and several others have hazardous components by nature. Compounds of unsaturated pyrrolizidine alkaloid, like senecionine, for instance, are hepatotoxic for people and shows carcinogenicity and mutagenesis in rats.

FUTURE PROSPECTS

Herbal medications are often used in both advanced and emerging nations for medical care. Yet, numerous high-profile plant potential problems in past years had an effect on the health, so there is growing acknowledgment of a need to create pharmacovigilance (quality surveillance) programs for herbal medications. The likelihood for natural medications to provide a significant detrimental influence on healthcare must be considered. Nonetheless, there is a similarity here between absence of a formalized pharmaceuticals regulatory structure prior to a thalidomide catastrophe as well as the contemporary scenario in several industrialized and developing nations wherein herbal supplements are uncontrolled. Natural medications, particularly imported plants without any usual meaning in the importing nation, are marketed in these nations with no obligation to notify the pharmaceutical authorities or show purity, efficacy, and potency.

The existing pharmacovigilance concept and techniques were created in connection to conventional pharmaceuticals, and using those techniques to assessing the efficacy of herbal supplements offers new problems in contrast to all those outlined for standard treatments. Many additional techniques employed in traditional medicine pharmacovigilance, like prescription-event surveillance including the use of electronic medical records repositories, are presently of less value in analysing the efficacy of herbal medications. Additional long-term advancements in alternative medicine surveillance could include changes to existing methodologies, consumer feedback, and a stronger emphasis on pharmacogenetics in enhancing the reliability of herbal medications[42].

REFERENCES

1. World Health Organization. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. World Health Organization. (2004).

2. Williamson E. Drug interactions between herbal and prescription medicines. Drug Saf. 2003; 26:1075.
3. Jordan SA, Cunningham DG, Marles RJ. Assessment of herbal medicinal products: Challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol. 2010; 243:198–216.
4. Farah MH, Edwards R, Lindquist M, Leon C, Shaw D. International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiol Drug Saf. 2000; 9:105–12.
5. Gardiner P, Graham RE, Legedza AT, Eisenberg DM, Phillips RS. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med. 2006; 166(18):1968-74.
6. Barnes J, Mills SY, Abbot NC, Willoughby M, Ernst E. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol. 1999; 45 (5):496-500.
7. Kitai E, Vinker S, Sandiuk A, Hornik O, Zeltcer C, Gaver A. Use of complementary and alternative medicine among primary care patients. Fam Pract. 1998;15(5):411-4.
8. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf. 2003;12(1):17-29.
9. Angerhofer CK. Herbal Medicines, a Guide for Healthcare Professionals, Second Edition by Barnes J, Anderson AL, Phillipson JD. Pharmaceutical Press, London, UK. 2002. J Nat Prod. 2002; 65(12):1964–1964.
10. Kressman S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002; 54: 661-9.
11. Blume HH, Schug BS. Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary? Eur J Drug Metab Pharmacokinet. 2000; 25(1):41-8.
12. Vaidya AD, Devasagayam TP. Current status of herbal drugs in India: an overview. J Clin Biochem Nutr. 2007; 41(1):1-11.
13. Gulian C, Barnes J, Francis S-A. Types and preferred sources of information concerning herbal medicinal products: face-to-face interviews with users of herbal medicinal products. Int J Pharm Prac 2002; 10(S1):R33-R33.
14. Brown CM, Barner JC, Shah S. Community pharmacists' actions when patients use complementary and alternative therapies with medications. J Am Pharm Assoc (2003) 2005; 45(1):41–47.
15. Vickers AJ, Rees RW, Robin A. Advice given by health food Gene-stores: is it clinically safe? J R Coll Phys Lond 1998; 32 (5): 426-8.
16. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998; 280(18):1569-75.
17. MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002; 35: 166-73.
18. De Smet PAGM. Toxicological outlook on the quality assurance of herbal remedies. In: De Smet PAGM, Keller K, Hansel R. et al., Editors. Adverse effects of herbal drugs. Vol I. Heidelberg: Springer-Verlag, p.1-72;1992.
19. Busse W. The significance of quality for efficacy and safety of herbal medicinal products. Drug Inf J 2000; 34: 15-23.
20. De Smet PAGM. Health risks of herbal remedies. Drug Saf. 1995; 13 (2): 81-93. De Smet PAGM, Keller K, Hansel R, Chandler FR. Adverse effects of herbal drugs. Vol. 3. Berlin: Springer- 2003. In press Verlag, 1997. A
21. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006; 29(5):385-96.
22. McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, Avery A; Yellow Card Collaboration. Adverse drug reaction reporting in the UK: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf. 2010; 33(9):775-88.
23. Menniti-Ippolito F, Mazzanti G, Santuccio C, Moro PA, Calapai G, Firenzuoli F, Valeri A, Raschetti R. Surveillance of suspected adverse reactions to natural health products in Italy. Pharmacoepidemiol Drug Saf. 2000; 17(6):626-35.
24. Saokaew S, Suwankesawong W, Permsuwan U, Chaiyakunapruk N. Safety of herbal products in Thailand: an analysis of reports in the thai health product vigilance center database from 2000 to 2008. Drug Saf. 2011; 34(4):339-50.
25. Dennehy CE, Tsourounis C, Horn AJ. Dietary supplement-related adverse events reported to the California Poison Control System. Am J Health Syst Pharm. 2005; 62(14):1476-82.
26. Gryzlak BM, Wallace RB, Zimmerman MB, Nisly NL. National surveillance of herbal dietary supplement exposures: the poison control center experience. Pharmacoepidemiol Drug Saf. 2007; 16(9):947-57.
27. Gardiner P, Sarma DN, Low Dog T, Barrett ML, Chavez ML, Ko R, Mahady GB, Marles RJ, Pellicore LS, Giancaspro GI. The state of dietary supplement adverse event reporting in the United States. Pharmacoepidemiol Drug Saf. 2008;17(10):962-70.
28. Perharic L, Shaw D, Leon C, De Smet PA, Murray VS. Possible association of liver damage with the use of Chinese herbal medicine for skin disease. Vet Hum Toxicol. 1995; 37(6):562-6.
29. McRae CA, Agarwal K, Mutimer D, Bassendine MF. Hepatitis associated with Chinese herbs. Eur J Gastroenterol Hepatol. 2002; 14(5):559-62.
30. Shaw D. Investigation of liver toxicity of Chinese herbal medicine: pilot case-control study. Drug Safety 2010b; 33:918–919.
31. Bailey D. Stockley's Herbal Medicines Interactions. Br J Clin Pharmacol. 2011;71(1):143.
32. Mehta UC. Pharmacovigilance: The devastating consequences of not thinking about adverse drug reactions: CME: Continuing Medical Education, 2011; 29(6):247.
33. WHO Drug Dictionary. Uppsala Monitoring Centre electronic database, updated quarterly.
34. Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev. 2011; 5(9): 103-10.
35. Adams CD. Stockley's Drug Interactions. Tenth edition, Stockley's Drug Interactions Pocket Companion 2013. J Med Libr Assoc. 2014; 102(3):221.
36. Chan AL, Leung HW, Wu JW, Chien TW. Risk of hemorrhage associated with co-prescriptions for Ginkgo biloba and antiplatelet or anticoagulant drugs. J Altern Complement Med. 2011; 17(6): 513-7.
37. Chen CH, Dickman KG, Huang CY, Moriya M, Shun CT, Tai HC, Huang KH, Wang SM, Lee YJ, Grollman AP, Pu YS. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: Clinical characteristics and outcomes. Int J Cancer. 2013; 133(1):14-20.
38. Mei N, Guo L, Fu PP, Fuscoe JC, Luan Y, Chen T. Metabolism, genotoxicity, and carcinogenicity of comfrey. J Toxicol Environ Health B Crit Rev. 2010; 13(7-8):509-26.
39. World Health Organization. WHO policy perspectives on medicines. Pharmacovigilance: ensuring the safe use of medicines. Geneva: World Health Organization, 2004.
40. Giveon SM, Liberman N, Klang S, Kahan E. Are people who use "natural drugs" aware of their potentially harmful side effects and reporting to family physician? Patient Educ Couns 2004; 53: 5–11.
41. Chan TY, Chan AY, Critchley JA. Hospital admissions due to adverse reactions to Chinese herbal medicines. J Trop Med Hyg 1992; 95(4): 296–8.

42. Loew D, Kaszkin M. Approaching the problem of bioequivalence of herbal medicinal products. Phytother Res 2002; 16: 705–11.